OTC · Biotechnology

Brii Biosciences Limited (BRIBF) Stock

$0.13 +0.00% OTC: BRIBF Healthcare

Brii Biosciences Limited, established in 2017 and headquartered in Beijing, China, is dedicated to advancing therapeutic solutions for infectious diseases and disorders affecting the central nervous system. Their diverse pipeline includes BRII-778 and BRII-732, both progressing through Phase I clinical trials for HIV patients.

Valuation

MetricValue
Price$0.13
Market Cap$90.69M
P/E Ratio-2.71
P/B Ratio0.24
P/S Ratio30.22
EPS (TTM)$-0.30
52-Week High$0.25
52-Week Low$0.13
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-8.92%
ROA-9.19%
ROCE-12.71%
Gross Margin84.78%
Operating Margin-1644.44%
Net Margin-1205.56%
Debt/Equity0.00
Current Ratio60.73

Annual Financials (USD)

Metric20212022202320242025
Revenue$93.0M$52.0M$1.0M$50.0M$18.0M
Operating Profit$-610.0M$-514.0M$-544.0M$-404.0M$-296.0M
Net Profit$-4.1B$-484.0M$-175.0M$-508.0M$-217.0M
EPS$-9.48$-0.67$-0.24$-0.70$-0.30
Op Margin-659.7%-995.3%-88217.3%-808.7%-1632.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.6B$3.4B$3.2B$2.7B$2.4B
Total Liabilities$300.0M$234.0M$126.0M$101.0M$36.0M
Cash$2.9B$1.2B$490.0M$1.0B$609.0M
Borrowings$22.0M$13.0M$3.0M$28.0M$9.0M

Latest News

Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B PR Newswire · Jul 3, 2026 Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV PR Newswire · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-879.0M$-496.0M$-594.0M$-373.0M$-287.0M
Investing Cash Flow$-477.0M$-1.6B$-154.0M$892.0M$-153.0M
Financing Cash Flow$-88.0M$6.0M$-1.0M$-3.0M$-22.0M
Net Cash Flow$1.8B$-1.7B$-701.0M$514.0M$-424.0M
Free Cash Flow$-880.0M$-636.0M$-644.0M$-376.0M$-288.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA0.06
FCF Yield-53.55%
Quick Ratio60.73
Interest Coverage-4932.94
Return 1Y-45.61%
Return 3Y-71.74%
Return 5Y—

Ownership

Insiders Held5.02%
Institutions Held12.84%
Institutions Float Held13.52%
Institutional HolderSharesReport Date
American Century ETF Trust-Avantis Emerging Markets Equity ETF697,0002026-06-30
SPDR INDEX SHARES Fd.S-State Street SPDR S&P Emerging Markets Small Ca504,5002026-06-30
DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT.186,5002026-04-30
DFA INVESTMENT DIMENSIONS GROUP INC-World ex U.S. Core Eqy. PORT.133,5002026-04-30
American Century ETF TRT-Avantis Responsible Emerging Markets Eqy. ETF50,5002026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCCOYBICO Group AB (publ) $0.37 +0.00% -1.07 $104.11M 0.00%
BXPHFBotanix Pharmaceuticals Limited $0.02 -30.23% -0.41 $29.89M 0.00%
CLLKFBICO Group AB (publ) $1.53 +0.00% -1.07 $105.68M 0.00%
GNFTFGenfit S.a. $15.95 +0.00% -8.14 $799.03M 0.00%
IPHYFInnate Pharma S.A. $1.65 +0.00% -2.84 $154.94M 0.00%

About Brii Biosciences Limited

Brii Biosciences Limited, established in 2017 and headquartered in Beijing, China, is dedicated to advancing therapeutic solutions for infectious diseases and disorders affecting the central nervous system. Their diverse pipeline includes BRII-778 and BRII-732, both progressing through Phase I clinical trials for HIV patients. For Hepatitis B (HBV), they are evaluating BRII-179 and BRII-835 in a combined Phase 2 study; BRII-179 also stands as a recombinant protein-based HBV immunotherapeutic in Phase 1b/2a, while BRII-835 has completed Phase 2 for chronic HBV patients. Additionally, the Amubarvimab/romlusevimab combination therapy is under development for COVID-19. In the CNS arena, BRII-296 targets postpartum depression (PPD) and BRII-297 addresses various depressive disorders. Their anti-infective portfolio features BRII-636, BRII-672, and BRII-693, designed to combat multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections, alongside BRII-658 for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.

Brii Biosciences Limited is headquartered in CN.

Brii Biosciences Limited (BRIBF) stock trades at $0.13 with a market capitalization of $90.69M. The stock is valued at a price-to-earnings (P/E) ratio of -2.71, price-to-book of 0.24, price-to-sales of 30.22. Over the past 52 weeks the stock has ranged between $0.13 and $0.25, and currently trades 48.0% below its 52-week high.

On profitability, Brii Biosciences Limited generates a return on equity (ROE) of -8.92%, return on capital employed of -12.71%, an operating margin of -1644.44%, a net profit margin of -1205.56%.

Official website: www.briibio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides